| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Ranolazine | FAERS: 4 | US FAERS | |
| 2 | MDV 3100 | FAERS: 2 | US FAERS | |
| 3 | ponatinib | FAERS: 2 | US FAERS | |
| 4 | Bosentan | FAERS: 1 | US FAERS | |
| 5 | Dabigatran | FAERS: 1 | US FAERS | |
| 6 | Liraglutide | FAERS: 1 | US FAERS | |
| 7 | N-carbamylglutamate | FAERS: 1 | US FAERS | |
| 8 | NuvaRing | FAERS: 1 | US FAERS | |
| 9 | Rivaroxaban | FAERS: 1 | US FAERS | |
| 10 | Roflumilast | FAERS: 1 | US FAERS | |
| 11 | Sitagliptin Phosphate | FAERS: 1 | US FAERS | |
| 12 | Sorafenib | FAERS: 1 | US FAERS | |
| 13 | Tiotropium Bromide | FAERS: 1 | US FAERS | |
| 14 | apixaban | FAERS: 1 | US FAERS | |
| 15 | macitentan | FAERS: 1 | US FAERS | |
| 16 | teriflunomide | FAERS: 1 | US FAERS |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120326
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.